Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
   
Ask the Experts About

Women and HIVWomen and HIV
           
Rollover images to visit our other forums!
  
  • Email Email
  • Glossary Glossary


side effects
Nov 16, 2001

Doctors, Of the two PI's, ritonavir and nelfinavir, recomended for treatment in HIV infected infants, which one is better tolerated with the least amount of potential side effects? Is there another PI that you would recommend to take with AZT and 3TC that is equally or better tolerated for infants? Thank you ahead for your response.

Response from Dr. Luzuriaga

Nelfinavir and ritonavir are the 2 PI's for which we have the best pharmacokinetic and safety data across the age spectrum in pediatrics. We have very sparse data on the pk and safety of the other PI's in young infants. In general, nelfinavir is more palatable than ritonavir and thus is more widely used. Another reason that we often like to begin with nelfinavir is that the most common resistance mutation associated with nelfinavir (D30N) does not necessarily confer cross-resistance to other PI's. Both have excellent safety profiles in young infants.


Previous
father +mother hiv + can they healthy baby ?
Next
First CD4 & Viral load in

  
  • Email Email
  • Glossary Glossary


 
 
Advertisement




Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement